Want to see JP:4584 full AI Analyst Report?
Kidswell Bio Corporation (4584) AI Stock Analysis
Kidswell Bio Corporation
(TSE/TYO:4584)
The score is held down primarily by weak financial quality—volatile profitability, elevated leverage, and a return to significant cash burn in the most recent year. Technicals provide some offset via improving short-term momentum, but extended oscillators and a still-weak longer-term trend limit that support, while valuation is constrained by negative earnings and no stated dividend yield.
Kidswell Bio Corporation (4584) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 7.00B
- Dividend Yield
- ―
- Average Volume (3M)
- 286.63K
- Price to Earnings (P/E)
- -17.8
- Beta (1Y)
- 1.14
- Revenue Growth
- -2.86%
- EPS Growth
- -210.09%
- Country
- Japan
- Employees
- 32
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Kidswell Bio Corporation Business Overview & Revenue Model
Company Description
Kidswell Bio Corporation, headquartered in Tokyo, Japan, specializes in the development of pharmaceutical treatments for rare and complex diseases. The company, which was founded in 2001 and operated as Gene Techno Science Co.,Ltd. until rebranding i...
How the Company Makes Money
Kidswell Bio’s monetization is primarily tied to the biopharmaceutical development model. Revenue may be generated through (1) licensing and out-licensing arrangements (e.g., upfront payments, milestone payments tied to development/approval events, a...
Kidswell Bio Corporation Financial Statement Overview
Summary
Revenue has grown strongly over the period, but fundamentals remain high risk: profitability is inconsistent with a return to losses in 2026, leverage is elevated (debt-to-equity ~1.54) for an unprofitable profile, and cash flow flipped back to material burn in 2026 after a single strong year in 2025.
Income Statement
44NeutralBalance Sheet
38NegativeCash Flow
32Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.14B | 6.59B | 5.08B | 2.43B | 2.78B | 1.57B |
| Gross Profit | 1.58B | 1.75B | 1.64B | 1.04B | 1.53B | 1.02B |
| EBITDA | -217.23M | -138.26M | 116.26M | -1.38B | -620.45M | -531.89M |
| Net Income | -373.22M | -413.99M | -21.14M | -1.42B | -657.43M | -550.86M |
Balance Sheet | ||||||
| Total Assets | 6.13B | 6.09B | 7.01B | 5.09B | 3.89B | 3.47B |
| Cash, Cash Equivalents and Short-Term Investments | 3.23B | 3.29B | 3.00B | 2.23B | 1.07B | 1.16B |
| Total Debt | 2.48B | 2.55B | 1.84B | 2.58B | 1.95B | 700.00M |
| Total Liabilities | 4.29B | 4.43B | 5.60B | 4.25B | 2.66B | 1.77B |
| Stockholders Equity | 1.84B | 1.65B | 1.41B | 831.47M | 1.23B | 1.70B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -1.11B | 930.26M | -453.63M | -1.42B | -1.17B |
| Operating Cash Flow | 0 | -1.09B | 936.71M | -453.63M | -1.42B | -1.17B |
| Investing Cash Flow | 0 | -12.62M | 65.08M | 0 | -28.82M | 526.51M |
| Financing Cash Flow | 0 | 1.40B | -240.06M | 1.62B | 1.36B | 369.08M |
Kidswell Bio Corporation Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4584, the sentiment is Negative. The current price of 137.00 is below the 20-day moving average (MA) of 152.65, below the 50-day MA of 161.58, and below the 200-day MA of 194.88, indicating a bearish trend. The MACD of -4.56 indicates Positive momentum. The RSI at 30.49 is Neutral, neither overbought nor oversold. The STOCH value of 32.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4584.
Kidswell Bio Corporation Peers Comparison
Overall Rating
JP:459348Neutral- JP:458445Neutral
JP:497844Neutral
JP:777442Neutral
JP:459938Underperform
JP:777637Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| JP:4593 | 48Neutral | JPY 34.43B | 45.77 | ― | ― | -47.32% | ― |
| JP:4584 | 45Neutral | JPY 7.59B | -17.76 | ― | ― | -2.86% | -210.09% |
| JP:4978 | 44Neutral | JPY 12.39B | -22.88 | ― | ― | -18.71% | -246.54% |
| JP:7774 | 42Neutral | JPY 24.65B | -65.42 | ― | ― | 17.05% | 10.47% |
| JP:4599 | 38Underperform | JPY 8.15B | -3.77 | ― | ― | ― | 4.85% |
| JP:7776 | 37Underperform | JPY 7.18B | -5.52 | ― | ― | -56.16% | 3.12% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4584 | Kidswell Bio Corporation | 137.00 | -110.00 | -44.53% | |
| JP:4593 | Healios KK | 223.00 | -240.00 | -51.84% | |
| JP:4599 | StemRIM Inc. | 111.00 | -164.00 | -59.64% | |
| JP:4978 | ReproCELL Inc. | 106.00 | -64.00 | -37.65% | |
| JP:7774 | Japan Tissue Engineering Co., Ltd. | 586.00 | 119.00 | 25.48% | |
| JP:7776 | CellSeed Inc. | 160.00 | -259.00 | -61.81% |
Kidswell Bio Corporation Corporate Events
Kidswell Bio Balances Biosimilar Margin Gains With High-Growth Cell Therapy Push in FY2026 Q1
Kidswell Bio reported fiscal 2026 first-quarter consolidated net sales of ¥1.27 billion, down year on year as lower delivery volumes for some biosimilars offset steady manufacturing progress, while gross profit of ¥431 million and operating...
Kidswell Bio Boosts Q1 Profit Despite Lower Sales, Keeps Guidance Range Wide
Kidswell Bio reported consolidated net sales of ¥1.27 billion for the first quarter ended June 30, 2026, down 26.2% year on year, but improved profitability with operating income rising 17.3% to ¥216 million and net income attributable to o...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 21, 2026